NASDAQ NMS - GLOBAL MARKET · CTXR
-0.07% · -$0.0004 · Vol Not reported
Pre-market · updated 08:15:49 ET
Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc

Pharmaceuticals
$0.5750
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
CTXR
Citius Pharmaceuticals Inc
Mon Aug 24 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

49/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Mon Aug 24 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CTXR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CTXR catalysts
About Citius Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2011
Employees
23
Country
US

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.5754
Last session
Day high
$0.5754
Last session
Day low
$0.5754
Last session
Previous close
$0.5754
52W high
$1.82
-68.41% from high
52W low
$0.4806
7% of range
Market cap
$15.8M
EPS
$-2.4700
Beta
2.04
Shares out
27.5M
Avg volume
807.5K
VWAP
$0.5754
Last session
Price history computed in-house
1W
+0.56%
1M
+10.51%
3M
-16.67%
1Y
-54.37%
YTD
-26.00%
SMA 50 $0.5862 · below
SMA 200 $0.7853 · below
52W position 7%

CTXR overview

Veridion Score
49
Registered · 2026-08-24
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CTXR.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CTXR Form 4 filings
Public disclosures

Congress activity in CTXR

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CTXR in the cached public ledger.

Federal contracts

CTXR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CTXR in this window.
Lobbying spend

CTXR lobbying filings, year to date.

Registered lobbying filings matched to Citius Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CTXR in this window.
Loading news for CTXR
Analyst ratings
Sovereign unlock shows live analyst consensus for CTXR.
Options
Sovereign unlock shows live options positioning for CTXR.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.